Global BCMA-targeted CAR-T Cell Therapy Market Growth (Status and Outlook) 2025-2031

The global BCMA-targeted CAR-T Cell Therapy market size is predicted to grow from US$ 1764 million in 2025 to US$ 7036 million in 2031; it is expected to grow at a CAGR of 25.9% from 2025 to 2031.

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. BCMA stands for B - cell maturation antigen. It is a protein that is found on the surface of plasma cells, which are abnormal cells that multiply uncontrollably in multiple myeloma, a type of blood cancer. By targeting BCMA, the CAR - T cell therapy aims to specifically attack the cancer - causing plasma cells.

Major players: The BCMA-targeted CAR-T cell therapy market presents a highly concentrated duopoly. In 2024, the global market CR2 index exceeded 98%. The main products are Carvykti (Cedacion) jointly developed by Legend Biotech and Johnson & Johnson and Abecma of Bristol-Myers Squibb. Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.

Market Trends: The BCMA CAR - T cell therapy market is in a phase of rapid growth. The reasons for this growth are two - fold. Firstly, there is a large population of patients with multiple myeloma, and there are many unmet medical needs. Secondly, this therapy has demonstrated good efficacy and has been recognized by the market. With the maturation of technology and market promotion, it is expected that the market will maintain a high growth rate in the coming years.

Expansion of Indications: Currently, BCMA CAR - T cell therapy is mainly used for the treatment of relapsed or refractory multiple myeloma. With the deepening of research, its indications are expected to be broadened. Pre - clinical and clinical trials are exploring its application in other hematological malignancies, such as certain types of leukemia and lymphoma. If successful, this will greatly expand the market size, bring hope to more patients, and inject new impetus into the growth of the therapy market.

Changing Competitive Landscape：The market competition is becoming increasingly fierce. In addition to the already - launched products such as Ciltacabtagene Autoleucel (Carvykti) and Idecabtagene Vicleucel (Abecma), many pharmaceutical companies are actively deploying and researching BCMA CAR - T products. New entrants may change the existing competitive landscape with innovative technologies or better cost control.

High - Cost Constraints: The research, development, and production processes of BCMA CAR - T cell therapy are complex, involving multiple high - cost links such as cell collection, gene editing, and cell culture, resulting in high product prices. This makes it difficult for many patients to afford, limiting the accessibility of the therapy and, to a certain extent, hindering the rapid expansion of the market. How to reduce costs so that more patients can benefit is an important challenge faced by the entire industry.

Safety Risks：Although this therapy has achieved remarkable results in clinical applications, there are still certain safety risks, such as cytokine release syndrome (CRS) and neurotoxicity. These adverse reactions may have a serious impact on the health of patients and even endanger their lives.

LPI (LP Information)' newest research report, the “BCMA-targeted CAR-T Cell Therapy Industry Forecast” looks at past sales and reviews total world BCMA-targeted CAR-T Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected BCMA-targeted CAR-T Cell Therapy sales for 2025 through 2031. With BCMA-targeted CAR-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BCMA-targeted CAR-T Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global BCMA-targeted CAR-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on BCMA-targeted CAR-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global BCMA-targeted CAR-T Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BCMA-targeted CAR-T Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BCMA-targeted CAR-T Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of BCMA-targeted CAR-T Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Abecma
Carvykti
Others

Segmentation by Application:
Hospital
Oncology Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Nanjing Legend Biotechnology/J&J (Carvykti)
Bristol-Myers Squibb (Abecma)
CARsgen
Nanjing Iaso Biotherapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.